Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Intravitreal aflibercept for proliferative diabetic retinopathy

We congratulate Sobha Sivaprasad and colleagues (June 3, p 2193)1 for their interesting paper on the clinical efficacy of intravitreal aflibercept versus panretinal laser photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy (the CLARITY study). The authors concluded that aflibercept was non-inferior and superior to panretinal laser photocoagulation in both the modified intention-to-treat population and the per-protocol population. These findings provide new, provocative data that should be taken into consideration when formulating a treatment management plan for individuals with proliferative diabetic retinopathy.